1 Additionally, development of antibodies to risankizumab has been associated with lower RZB concentrations, reduced clinical response, hypersensitivity and infusion site reactions.2 "Prometheus ...

1 Additionally, development of antibodies to risankizumab has been associated with lower RZB concentrations, reduced clinical response, hypersensitivity and infusion site reactions. 2 "Prometheus ...

AbbVie’s psoriasis drug risankizumab has posted strong results in its latest phase 3 trial, as the company prepares to file the drug with global regulators. An interleukin-23 inhibitor ...

Skyrizi (risankizumab) is the first IL-23-selective drug to be cleared for the inflammatory bowel disease – ahead of rivals like Johnson & Johnson's Tremfya (guselkumab), and Sun Pharma's Ilumya ...

Crohn s disease is a chronic inflammatory disease of the gastrointestinal tract, mostly affecting the ileum. The inflammation can extend through the intestinal wall and tends to be asymmetric and ...